Lupin Ltd

NSE: LUPIN · BSE: 500257 · Pharmaceuticals & Biotechnology · 57 announcements

Lupin Ltd news stories on ALFA NewsRead the news →

Share price: ₹2,012.90
Market cap: ₹92,048 Cr
Revenue (annual): ₹27,958 Cr
Net profit (annual): ₹5,333 Cr
P/E (TTM): 16.6×Sector 47.4×
Promoter holding: 46.85%-0.01% QoQ
FII holding: 22.42%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

20 Aug 2026 10:46 IST NSE

PartnershipAlfa Alert

Lupin Partnership

Lupin Limited's subsidiary VISUfarma B.V. signed an exclusive license agreement with Visus Therapeutics to commercialize YUVEZZI™ in Europe. The deal includes potential consideration of €75 million.

Value: ₹832.5 Cr
Execution: Initial term until 20th anniversary of first commercial sale

Read the story on ALFA News Read the filing ↗

8 Jun 2026 12:13 IST NSE

Partnership

Lupin Partnership

Lupin collaborated with Laboratorios ERN S.A. to launch its Luforbec inhaler in Spain. This strategic partnership expands Lupin's respiratory market footprint into the Spanish therapeutic sector.

Read the filing ↗